[Cite as http://purl.org/au-research/grants/nhmrc/1039021]
Ms Suang Suang Koid
Brief description Cardiovascular disease is the leading cause of death in Australia. Aliskiren is the first renin inhibitor-type drug to be approved for clinical use for treatment of hypertension. The aim of this project is to evaluate the effectiveness of aliskiren for the treatment of heart attack and heart failure, as compared to existing therapies. Aliskiren may potentially replace or complement current therapies, thereby reducing death and improving health and economic benefits for the community.
Funding Amount $AUD 74,263.01
Funding Scheme Postgraduate Scholarships
Dora Lush Biomedical Postgraduate Scholarship